ProQR Therapeutics N.V. (PRQR)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.48
- As of
Kresmion compiles this page from PRQR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ProQR Therapeutics N.V. (PRQR): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-23.
See the full PRQR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PRQR on one page. Preview it with sample data, then open it live with a free account.
Preview the PRQR dossierActive signals for PRQR
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 31.2%, EPS $-0.08 vs $-0.1163 estimate
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 6.6% - EPS $-0.13 vs $-0.122 estimate
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 43.5% - EPS $-0.12 vs $-0.0836 estimate
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 18.8% - EPS $-0.084 vs $-0.1035 estimate
- mediumEARNINGS_MISS
Missed consensus by 6.6% - EPS $-0.13 vs $-0.122 estimate
FREE, NO ACCOUNT
Every signal on PRQR, as it fires
New filings, 13F moves and cross asset signals on PRQR land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, PRQR
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
PRQR against its peers
PRQR's operating margin of -273.1% ranks in the 45th percentile of 18 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | PRQR | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 15.9M EUR | n/a | n/a | 1 |
| Revenue YoY | -15.9% | n/a | n/a | 2 |
| Operating margin | -273.1% | -236.6% | 45 | 18 |
| Net margin | -265.2% | -436.5% | 53 | 19 |
| Return on equity | -85.4% | -56.3% | 44 | 23 |
| 1 year | n/a | -30.1% | n/a | 22 |
Peers (25): ALEC, PLX, NAGE, MGNX, PYXS, CAMP, ACOG, XGN, IFRX, STRO, SION, IVVD, RNAC, ELDN, SLGL, TRDA, GLSI, FATE, UPB, LRMR, LCTX, IMRX, LXEO, KROS, LYEL. Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (PRQR: 20-F), reported in EUR. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow PRQR on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to PRQR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.